SGS Acquires Keystone Bioanalytical to Expand North American Drug Development Testing Capabilities
核心洞察
SGS (搜索), the world's leading testing and certification company, has acquired Philadelphia-based Keystone Bioanalytical (搜索) to strengthen its bioanalytical testing services for North American pharmaceutical and biotech companies.
Keystone Bioanalytical (搜索) operates a 10,000 square foot GLP-compliant facility specializing in LC-MS/MS method development, validation, and analysis for both small and large molecule drug development across pre-clinical and clinical phases.
The acquisition supports SGS (搜索) Strategy 27 objectives to double North American sales between 2023 to 2027, responding to increasing regulatory demands from the FDA and Health Canada for high-quality bioanalytical testing services.
SGS (搜索), the world's leading testing, inspection and certification company, has acquired Keystone Bioanalytical (搜索), a specialized provider of bioanalytical testing services based in Philadelphia, Pennsylvania. The acquisition strengthens SGS's end-to-end drug development lifecycle testing capabilities for North American pharmaceutical and biotechnology industries.
Strategic Expansion in Bioanalytical Services
"Expanding our GLP-compliant, bioanalysis-focused capabilities within the SGS (搜索) North American network underscores our commitment to meeting the growing demand for high-quality bioanalytical services supporting small and large molecule drug development," said Joseph Bower, Head of Life Sciences at SGS in North America. "This is an exciting time for SGS as we keep pace with the momentum driving North American pharma and biotech companies to lead the way globally in bringing innovative medicines and therapies to market."
Established in 2001, Keystone Bioanalytical (搜索) specializes in quantitative liquid chromatography-mass spectrometry (LC-MS/MS) method development, validation, and analysis, including integrated biomarker analysis, as well as drug metabolite profiling and identification. The company operates a 10,000 square foot GLP-compliant facility that delivers bioanalysis across both pre-clinical and clinical phases of the drug development lifecycle, encompassing pharmacokinetics and clinical trial studies.
Meeting Regulatory Demands
In North America, stringent regulatory oversight by agencies such as the U.S. Food and Drug Administration (搜索) and Health Canada is driving continued demand for high-quality bioanalytical testing services. Keystone Bioanalytical (搜索)'s team has built a strong reputation for delivering rapid turnaround times on tailored and complex small molecule and biomarker projects, supporting pharmaceutical and biotech clients across the United States.
The acquisition of Keystone Bioanalytical (搜索) supports SGS (搜索) Strategy 27 objectives to double North American sales between 2023 to 2027 by responding to megatrends shaping growth in the TIC industry, including rising regulation and increasing expectations for safety, health and well-being.
Global Laboratory Network
SGS (搜索) has been supporting the North American pharmaceutical industry for over 30 years across the full drug development lifecycle. This regional expertise is complemented by a global network of 20+ laboratories across 11 countries, including 10 GLP-compliant sites, positioning SGS as one of the most comprehensive, wholly owned analytical laboratory networks serving the pharmaceutical and biotechnology sectors worldwide.
The company operates a network of over 2,500 laboratories and business facilities across 115 countries, supported by a team of over 100,000 dedicated professionals. With more than 145 years of service excellence, SGS (搜索) combines precision and accuracy to help organizations achieve the highest standards of quality, compliance and sustainability.